Renal Cancer
The changing trends of image-guided biopsy of small renal masses before intervention-an analysis of European multinational prospective EuRECA registry.
February 7, 2022
Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature.
February 4, 2022
Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma.
February 4, 2022
Improving accuracy, reliability, and efficiency of the RENAL nephrometry score with 3D reconstructed virtual imaging.
February 3, 2022
Decreased CDKL2 Expression in Clear Cell Renal Cell Carcinoma Predicts Worse Overall Survival.
February 3, 2022
The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis.
February 2, 2022
Decreased Expression of ACADSB Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma.
February 2, 2022
Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma.
January 31, 2022
Prognostic and Clinicopathological Correlations of Pretreatment Prognostic Nutritional Index in Renal Cell Carcinoma: A Meta-Analysis.
January 31, 2022
MicroRNA-155-5p targets NR3C2 to promote malignant progression of clear cell renal cell carcinoma.
January 28, 2022
Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor.
January 28, 2022
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
January 27, 2022
Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma.
January 27, 2022
Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
January 27, 2022